December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

113.64 -2.06 (-1.78%)
Delayed Quote Updated: 11:25 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
News headline image
New Indication Approval For Incyte "To Usher New Growth Avenue" ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Incyte ↗
Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter: 
Via Benzinga
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Twitter And 3 Other Stocks Insiders Are Selling ↗
US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them ↗
Four pharmaceutical stocks, including three biotech movers, are making big moves. 
Via Investor's Business Daily
News headline image
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
News headline image
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance ↗
 
Via Benzinga
News headline image
Incyte: Q1 Earnings Insights ↗
Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
7 Defensive Stocks to Buy for a Bear Market ↗
As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market. 
Via InvestorPlace
News headline image
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14 ↗
CNBC 
Via Benzinga
News headline image
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy ↗
Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration. 
Via Benzinga
News headline image
Insights On Incyte Corporation ↗
In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million... 
Via Talk Markets
News headline image
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review ↗
A confirmed market uptrend is reeling as inflation's pain bites. 
Via Investor's Business Daily
News headline image
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted ↗
 
Via Benzinga
News headline image
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
News headline image
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now ↗
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
News headline image
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19 ↗
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.